I have spoken to a recently retired pharmacist who has been in the pharmaceutical industry for 45 years and is recently retired. She was a hospital pharmacist, then became an owner of a couple of retail pharmacies, before starting a large compound pharmacy business (with several locations) which has recently been sold. She has participated in peer-reviewed research and has sub-contracted her services to a TGA department in the past. A family member of hers has listed two ASX companies in a different sector. This person has also received iPPS treatment and is familiar with the product, PAR.ASX and is VERY VERY familiar with its management (hence the reason I won't name this person).
I asked her about the product and investing in the company. She indicated that it is a good product and she received personal health benefit from using it, as did her husband, and she has seen some of her customers benefit from it and recommends the product. She said it is by no means a miracle drug but it did help her arthritic symptoms, and continues to give her benefit. She has had 2 follow-up doses.
As for investing in it... she refuses to and won't until PR is gone or she sees a rock-solid partnership signed in a medium sized country with a reputable pharmaceutical company
Lack of patent protection (yes, she is very familiar with efforts that have been put in place to attempt to protect from generics) and very poor management are 2 of the main reasons she won't currently invest in it. There were many other reasons listed as well, but not as significant as these two. She is not convinced that PR will get iPPS approved and to market, and also get the support of a large pharmaceutical company.
Personally, I hope she is wrong, however I respect her opinion and reasons.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)